United States Patent 8,865,187: Claim Scope, Validity Risks, and NSAID Patent Landscape

U.S. Patent No. 8,865,187 protects a narrowly defined NSAID-in-oil suspension using a soy-lecithin/sunflower-oil vehicle with specified compositional ranges. The strongest commercial embodiment is an aspirin suspension in lecithin oil, consistent with the technology later associated with phospholipid-based aspirin products. The patent does not broadly cover all phospholipid NSAID formulations, all aspirin products, or all compositions that reduce gastrointestinal toxicity.

The principal infringement questions are whether a competing product uses the specified lecithin-oil composition, whether its NSAID associates with a phospholipid, and whether the product satisfies the claimed reduced-GI-toxicity limitation.

What does U.S. Patent 8,865,187 cover?

The patent covers two independent composition claims.

Claim	Core subject matter	Key limitations
1	NSAID-in-oil suspension	Solid NSAID in soy-lecithin components dispersed in sunflower oil; specified PC, triglyceride, free-fatty-acid and glycolipid ranges; phospholipid association; therapeutic amount; reduced GI toxicity
2	Product-by-process composition	Same chemical and functional limitations, with the composition produced by admixing NSAID powder into the lecithin oil
3	Claim 1 species	Aspirin, indomethacin or ibuprofen
4	Claim 2 species	Aspirin, indomethacin or ibuprofen
5	Aspirin species	Claim 3 limited to aspirin
6	Aspirin species	Claim 4 limited to aspirin
7	Ratio limitation	NSAID-to-lecithin-oil ratio of about 4:1 to 1:4
8	Narrow ratio limitation	NSAID-to-lecithin-oil ratio of about 1:1
9	Process-claim ratio limitation	NSAID-to-lecithin-oil ratio of about 4:1 to 1:4
10	Process-claim ratio limitation	NSAID-to-lecithin-oil ratio of about 1:1

The patent issued on October 21, 2014. Its claim structure places most of the commercial value in claims 1, 3, 5, 7 and 8, particularly where the accused product is an aspirin-in-oil suspension.

What formulation is required by the patent?

Claim 1 requires a lecithin oil consisting of soy lecithin components in sunflower oil. The lecithin oil must fall within four compositional windows:

Component	Claimed range
Phosphatidylcholine	About 33-40 wt.%
Triglycerides	About 26-31 wt.%
Free fatty acids	About 8-13 wt.%
Glycolipids	About 5-9 wt.%

These limitations are cumulative. A formulation that meets the PC range but falls outside the triglyceride, free-fatty-acid or glycolipid ranges may avoid literal infringement of claim 1.

The claims do not identify a particular commercial lecithin supplier, trade name, capsule shell, excipient package, preservative, particle-size distribution or manufacturing equipment. A supplier’s product specification or batch certificate could therefore be important in an infringement analysis.

Does the patent cover all soy lecithin formulations?

No. The claims require a lecithin oil with the specified compositional profile. A product using soy lecithin in another carrier oil, such as medium-chain triglycerides, olive oil or corn oil, would not literally satisfy the sunflower-oil limitation.

A formulation using non-soy lecithin also falls outside the literal scope. The doctrine of equivalents could be asserted in some circumstances, but a patentee would face limits where the patent specification and prosecution history show that soy lecithin and sunflower oil were selected as deliberate claim boundaries.

What NSAIDs are protected?

The dependent claims specifically identify:

Aspirin, also known as acetylsalicylic acid
Indomethacin
Ibuprofen

Aspirin receives the narrowest express protection through claims 5 and 6. The independent claims are not limited to those three NSAIDs, provided the compound qualifies as a solid NSAID and satisfies the other limitations.

The claims do not require a particular aspirin dose. They also do not require an enteric coating, delayed release, extended release or a specific route of administration. The claimed product could therefore cover multiple oral presentation formats if the formulation limitations are met.

How does the patent define reduced gastrointestinal toxicity?

The claims require that the composition have GI toxicity reduced relative to the NSAID alone. This is a functional limitation rather than a stated numerical reduction.

The claim language does not specify:

The GI endpoint
The animal model or human study design
The comparator formulation
The dosage used for comparison
The minimum percentage reduction
Whether ulceration, bleeding, gastric irritation or another endpoint controls

This creates both breadth and litigation risk. The limitation may help distinguish prior art showing only a physical mixture, while also creating an evidentiary burden in enforcement. A patentee would generally need comparative evidence linking the claimed lecithin-oil formulation to reduced GI toxicity.

A generic or competing manufacturer could challenge the limitation by arguing that the product does not demonstrate reduced GI toxicity against the required comparator or that the limitation is indefinite, not enabled across the full claim scope, or unsupported for all covered NSAIDs.

What does "associated with a phospholipid" mean?

The claims require the NSAID to associate with a phospholipid of the lecithin oil. The language does not expressly require covalent bonding, a crystalline complex, a defined stoichiometric ratio or a particular spectroscopic signature.

The term could encompass an interfacial, molecular, colloidal or other noncovalent interaction. The precise construction would depend on the specification, prosecution history and expert evidence. Analytical methods potentially relevant to the issue include:

Differential scanning calorimetry
X-ray diffraction
Fourier-transform infrared spectroscopy
Nuclear magnetic resonance
Particle-size and dispersion testing
Solubility or dissolution testing
Separation and extraction studies

A product that simply suspends crystalline aspirin in an oil containing lecithin may present a dispute over whether the aspirin is "associated with" a phospholipid rather than merely co-dispersed.

What is the significance of the product-by-process claims?

Claim 2 and its dependents require the composition to be the product of admixing NSAID powder into the specified lecithin oil. The process language narrows the claim by identifying powder addition as the production route.

U.S. product-by-process doctrine generally evaluates the claimed product by its structural or functional characteristics, although the process may matter where it produces a materially different product or where the claim language makes process identity relevant. The leading Federal Circuit authority is In re Thorpe, which recognizes that product-by-process claims are assessed primarily by the product itself for patentability purposes (In re Thorpe, 1985).

For enforcement, a process limitation can create a proof problem. A patentee may need manufacturing records, batch instructions, powder-addition data or process discovery to show that the accused product was made by the claimed route. A competitor using a preformed NSAID-phospholipid complex, solvent-mediated loading or a different incorporation sequence may have a stronger noninfringement position, depending on claim construction.

How broad are the ratio claims?

Claims 7 and 9 cover an NSAID-to-lecithin-oil weight ratio from approximately 4:1 to 1:4. Claims 8 and 10 narrow the ratio to approximately 1:1.

Ratio	Practical significance
4:1	High NSAID loading relative to lecithin oil
1:1	Specific central embodiment
1:4	High lecithin-oil content

"About" introduces numerical tolerance, but it does not eliminate the need to determine the relevant measurement method, batch variability and rounding convention. A formulation at 4.1:1 may raise a dispute over whether it is within the claimed range, while a formulation at 6:1 is more clearly outside the literal range.

What are the principal design-around options?

A competitor could target one or more claim elements:

Design-around strategy	Potential effect
Use a carrier oil other than sunflower oil	Avoids a central composition limitation
Use non-soy lecithin	Avoids the specified lecithin source
Use lecithin outside one or more compositional windows	Avoids literal range coverage
Use a preformed phospholipid complex	May avoid the powder-admixing process limitation
Use a solid NSAID other than the listed species	Avoids claims 3-6, but not necessarily claims 1 or 2
Use an NSAID-to-oil ratio outside 4:1 to 1:4	Avoids claims 7-10
Formulate NSAID as a solution rather than a suspension	May avoid the suspension limitation
Exclude phospholipid association	Creates a factual and technical noninfringement position
Use an enteric-coated tablet or conventional solid dosage form	Avoids the claimed NSAID-in-oil suspension

The strongest design-around is likely a formulation that changes both the lecithin source and the carrier oil. Changing only the ratio may avoid dependent claims while leaving claims 1 and 2 exposed.

How strong is the patent estate?

The patent has meaningful commercial relevance because its claims combine specific formulation chemistry with a therapeutic performance limitation. Its weaknesses arise from the same features.

Strengths

The lecithin-oil composition is defined by multiple quantitative ranges.
The claims target a formulation architecture rather than only a method of treating pain.
Aspirin is expressly protected in claims 5 and 6.
The claims cover both the formulation and a powder-admixing production route.
The GI-toxicity limitation can distinguish conventional NSAID formulations and some earlier physical mixtures.

Vulnerabilities

Prior art may disclose NSAID-phospholipid complexes or lipid vehicles for reducing gastric irritation.
The claims require proof of phospholipid association, which may be analytically contested.
"Reduced GI toxicity" lacks a numerical threshold and defined test protocol.
The claim set may face written-description or enablement scrutiny across aspirin, indomethacin, ibuprofen and other NSAIDs.
The narrow compositional ranges create potential noninfringement positions based on supplier or batch composition.
Claim 2 may be difficult to enforce without access to manufacturing evidence.

The patent is stronger against a product intentionally copied from the claimed lecithin-oil system than against a technically distinct phospholipid NSAID platform.

What is the FDA and Orange Book status?

U.S. Patent 8,865,187 does not establish FDA approval or FDA exclusivity. Patent rights and FDA regulatory exclusivity are separate.

Aspirin products marketed under the FDA over-the-counter framework generally do not receive NDA-based Orange Book listings in the same manner as prescription products approved under an NDA. Aspirin is regulated under the FDA OTC drug framework, including the analgesic, antipyretic and antirheumatic monograph provisions in 21 C.F.R. Part 343 (FDA, 2023).

Consequently:

A conventional OTC aspirin product does not create a standard Orange Book Paragraph IV pathway.
Patent 8,865,187 is not equivalent to an Orange Book-listed patent.
An OTC competitor may face patent infringement exposure without filing an ANDA.
FDA monograph compliance does not resolve patent infringement.
Patent expiration remains commercially relevant even where no Orange Book listing exists.

Are Paragraph IV challenges relevant?

A conventional Paragraph IV challenge is generally associated with an ANDA referencing an NDA-listed drug and patent. That pathway is not the normal route for an OTC aspirin product marketed under the monograph system.

The absence of a conventional Paragraph IV pathway does not remove patent risk. A competitor could instead:

Launch an OTC product and face district-court litigation.
Seek a declaratory judgment regarding noninfringement or invalidity.
Develop a formulation outside the patent claims.
Pursue a different regulatory route if the product’s labeling and clinical claims require one.

What patent litigation and settlements affect the patent?

The claim text alone does not establish litigation, settlement or licensing activity. Patent ownership, assignment history, maintenance-fee status, terminal disclaimers, continuations and court proceedings must be distinguished from the issued claims.

The principal diligence points are:

Issue	Commercial impact
Current assignee	Determines enforcement and licensing authority
Maintenance fees	Nonpayment can cause expiration before the nominal term
Continuations and divisionals	May preserve related claim scope after the parent expires
Reexamination or post-grant proceedings	Can narrow or cancel claims
District-court litigation	May produce claim-construction precedent
Settlement agreements	May permit or delay competitor entry
License agreements	May divide rights by product, territory or channel

A competitor should not treat the absence of an Orange Book listing as evidence that the patent is unenforceable.

Does the patent create biosimilar risk?

No meaningful biosimilar issue arises from this patent. Aspirin, ibuprofen and indomethacin are small-molecule NSAIDs, not biologics. The relevant competitive risks are generic, OTC, reformulated and private-label products rather than biosimilars.

The patent may still affect branded line extensions, prescription-strength formulations, hospital products and consumer-health products that use the claimed oil suspension.

What is the likely generic and commercial entry risk?

The greatest risk is from a product that reproduces all of the following:

Aspirin or another solid NSAID.
Soy lecithin components in sunflower oil.
The claimed PC, triglyceride, free-fatty-acid and glycolipid ranges.
NSAID association with lecithin phospholipid.
Reduced GI toxicity relative to NSAID alone.
A ratio within 4:1 to 1:4, where claims 7 or 9 are asserted.

A conventional aspirin tablet, enteric-coated aspirin tablet, ibuprofen suspension in water, or lipid formulation using a different oil would present a materially different infringement profile.

Geographic coverage

The patent is enforceable only in the United States. Parallel protection would require separate patents in other jurisdictions. Foreign patent families, national-phase applications, continuation rights and local validity outcomes must be analyzed independently. A U.S. patent does not block manufacture, sale or use outside the United States unless separate rights exist.

Key Takeaways

U.S. Patent 8,865,187 is a formulation patent directed to an NSAID suspension in a narrowly specified soy-lecithin/sunflower-oil vehicle.
Aspirin is expressly covered by claims 5 and 6.
The four lecithin-oil composition ranges are cumulative and create substantial design-around opportunities.
The "phospholipid association" and "reduced GI toxicity" limitations are central enforcement issues.
Claims 7-10 add NSAID-to-lecithin-oil ratio limitations, including the specific 1:1 embodiment.
The patent does not broadly cover all aspirin products, all phospholipid complexes or all GI-protective NSAID formulations.
Product-by-process claim 2 may require manufacturing-process discovery in litigation.
Paragraph IV is generally not the expected route for a monograph-based OTC aspirin product.
Biosimilar risk is not relevant; the competitive risks are generic and OTC formulation products.
Patent term, maintenance status, assignments, continuations, licenses and litigation must be assessed from the USPTO and court records rather than from the claims alone.

FAQs About U.S. Patent 8,865,187

Can a conventional aspirin tablet infringe U.S. Patent 8,865,187?

Ordinarily, no. A conventional tablet does not satisfy the NSAID-in-oil suspension, lecithin-oil composition and phospholipid-association limitations.

Does using sunflower oil alone avoid the patent?

Not necessarily. Sunflower oil alone lacks the required soy-lecithin components, but an accused product using sunflower oil with qualifying soy lecithin could remain within the claim scope.

Does the patent cover ibuprofen products?

Claims 3 and 4 expressly identify ibuprofen. The product must also satisfy the lecithin-oil, phospholipid-association, therapeutic-effect and reduced-GI-toxicity limitations.

Can a competitor avoid the patent by changing the aspirin-to-oil ratio?

Changing the ratio may avoid claims 7-10, but it does not necessarily avoid independent claims 1 and 2, which do not contain the expressly stated ratio limitation.

Is U.S. Patent 8,865,187 an Orange Book patent?

The patent itself is not an FDA Orange Book listing. Its commercial significance is primarily as a U.S. patent applicable to products marketed under the OTC aspirin framework.

References

U.S. Patent No. 8,865,187. (2014). Pharmaceutical composition comprising a non-steroidal anti-inflammatory drug in an oil suspension. United States Patent and Trademark Office.
In re Thorpe, 777 F.2d 695 (Fed. Cir. 1985).
U.S. Food and Drug Administration. (2023). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	414542	⤷ Start Trial
Australia	2001297778	⤷ Start Trial
Brazil	0116380	⤷ Start Trial
Canada	2431606	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,865,187

Summary for Patent: 8,865,187